Lilly ADA
Biotech

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
Fraiser Kansteiner Jun 6, 2026 3:28pm
Pfizer ADA

ADA: Pfizer pads case for berobenatide in obesity

Jun 6, 2026 9:29am
Roche

ADA: Roche, Zealand make tolerability case for petrelintide

Jun 7, 2026 3:00am
USA China flag

How RA Capital is offering ‘Chinese clinical expertise in a box’

Jun 5, 2026 8:19am
EULAR poster room

Cullinan's new data makes clearest case yet for autoimmune TCEs

Jun 6, 2026 5:15am
EULAR London 2026

Affibody gets izokibep ‘back on track’ after Acelyrin rejection

Jun 5, 2026 10:42am
More News

Fierce Biotech Layoff Tracker 2026: Fulcrum, Novartis & more

Jun 5, 2026 9:45am

AstraZeneca adds FDA cell and gene veteran—Chutes & Ladders

Jun 5, 2026 8:30am

At CNPV hearing, industry support meets ‘concern’ from experts

Jun 5, 2026 5:00am

Autobahn races toward ph. 3 after midstage bipolar depression win

Jun 4, 2026 11:31am